Effect of Qiliqiangxin capsule on NT-proBNP, LVEF and Tei index in elder patients with chronic heart failure

doi:10.3877/cma.j.issn.2095-2015.2018.05.006

Abstract

Abstract:

Objective

To investigate the effect of Qiliqiangxin capsule on clinical efficacy, N-terminal pro-brain natriuretic peptide(NT-proBNP), left ventricular ejection fraction(LVEF)and Tei index in elder patients with chronic heart failure(CHF).

Methods

A total of 170 elder patients with CHF were collected from June 2014 to July 2015 in the clinic of Yunnan Second People′s Hospital.All the patients were randomly divided into two groups by random number table method.In the control group, 85 patients were treated with standard treatment for heart failure.In the treatment group, 85 patients were given Qiliqangxin capusule additionally(4 granules, 3 times daily). The course of treatment was 3 months.The clinical efficacy, NT-proBNP, left ventricular end-diastolic diameter(LVEDD), LVEF and Tei index of both groups were observed and compared before and after treatment.

Results

After 3 months of treatment, clinical efficacy of the treatment group was significantly higher than that in the control group(88.1% vs.63.4%, P<0.05). In both groups, NT-proBNP levels, LVEDD and Tei index were significantly reduced after treatment(P<0.05), and LVEF was significantly increased(P<0.05). In addition, the improvements of the above indicators in the treatment group were better than those in the control group(P<0.05). Side effects were neither found in the two groups.

Conclusion

Qiliqiangxin capsule can further reduce the level of NT-proBNP, LVEDD and Tei index, increase LVEF, and improve the cardiac function in elder CHF patients who received standard heart failure treatment with good safety.

Key words: Heart failure, Qiliqiangxin capsule, N-terminal pro-brain natriuretic peptide, Left ventricular ejection fraction, Tei index

Miao Chen, Yingxia Guan, Lijuan Song, Chuannan Zou, Bei Yang, Yijian Zhang. Effect of Qiliqiangxin capsule on NT-proBNP, LVEF and Tei index in elder patients with chronic heart failure[J]. Chinese Journal of Digestion and Medical Imageology(Electronic Edition), 2018, 08(05): 213-216.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhxhbyyxzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-2015.2018.05.006

https://zhxhbyyxzz.cma-cmc.com.cn/EN/Y2018/V08/I05/213

Figures/Tables 2

References 19

1	顾东风，黄广勇，何江，等．中国心力衰竭流行病学调查及其患病率[J]．中华心血管病杂志，2003，31(1): 3-6
2	中国心血管病报告编写组．《中国心血管病报告2016》概要[J]．中国循环杂志，2017，32(6): 521-530.
3	周京敏，崔晓通，葛均波．中国心力衰竭的流行病学概况[J]．中华心血管病杂志，2015，43(12): 1018-1021.
4	张健，张宇辉．多中心、前瞻性中国心力衰竭注册登记研究——病因、临床特点和治疗情况初步分析[J]．中国循环杂志，2015，30(5): 413-416.
5	李琳，莫卿，莫婷，等．老年CHF患者临床特征和药物治疗状况多中心回顾性分析[J]．中华医学杂志，2018，98(9): 673-677.
6	刘蕊，卜丽梅．老年CHF的治疗进展[J]．中国老年学杂志，2013，33(23): 6059-6061.
7	魏聪，贾振华，吴以岭，等．芪苈强心胶囊对兔实验性CHF心室重构的保护作用[J]．疑难病杂志，2007，6(3): 144-147.
8	Zou Y, Lin L, Ye Y, et al.Qiliqiangxin inhibits the development of cardiac hypertrophy, remodeling, and dysfunction during 4 weeks of pressure overload in mice[J]. J Cardio Pharmacol, 2012, 59(3): 268-280.
9	徐涛，郭丽峰，陈立锋，等．芪苈强心胶囊对慢性心力衰竭大鼠心肌细胞凋亡的影响[J]．中药新药与临床药理，2010，21(4): 366-369.
10	Zhang J, Wei C, Wang H, et al.Protective effect of qiliqiangxin capsule on energy metabolism and myocardial mitochondria in pressure overload heart failure rats[J]. Evid Based Complement Alternat Med, 2013, 2013: 378298.
11	马柳一，尹玉洁，张军芳，等．芪苈强心胶囊对慢性心衰大鼠下丘脑室旁核RAS系统及交感神经系统的影响[J]．中国药理学通报，2016，32(4): 575-580.
12	韩安邦，张健，路迎冬，等．芪苈强心胶囊对心肌梗死大鼠心肌纤维化及TGF-β1/Smad3信号通路的影响[J]．北京中医药大学学报，2017，40(1): 41-47.
13	Bettencourt P. NT-proBNP and BNP: biomarkers for heart failure management[J]. Eur J Heart Fail, 2014, 6(3): 359-363.
14	黄创，李霖，郭鹏，等．N末端B型钠尿肽前体与老年心功能不全相关性的临床研究[J/CD]．中国医学前沿杂志(电子版)，2014，6(8): 85-88.
15	Huynh K. Heart failure: Improvement of LVEF in patients with HF is linked to better prognosis[J]. Nature Rev Cardiol, 2016, 13(9): 505.
16	Larina VN, Biu B, Dergunova EN, et al.Prognostic value of the myocardial performance(Tei)index in patients with chronic heart failure[J]. Kardiologiia, 2013, 53(11): 37.
17	Ogunmola OJ, Akintomide AO, Olamoyegun AM.Relationship between clinically assessed heart failure severity and the Tei index in Nigerian patients[J]. Bmc Res Notes, 2013, 6(1): 1-6.
18	刘树峰，严晓红，肖敦宏，等．芪苈强心胶囊辅治慢性心力衰竭患者的疗效及其对NT-proBNP、LVEF及Tei指数的影响[J]．疑难病杂志，2017，16(5): 505-508.
19	唐淑云，王登旭，燕芳芳，等．芪苈强心胶囊对慢性心力衰竭患者的治疗作用[J]．中国老年学杂志，2013，33(17): 4106-4108.

组别	例数	显效	有效	无效	总有效率	χ²值	P
治疗组	84	26(31.0)	48(57.1)	10(11.9)	88.1	8.797	0.003
对照组	85	19(22.4)	40(41)	26(30.6)	63.4	8.797	0.003

组别	例数	显效	有效	无效	总有效率	χ²值	P
治疗组	84	26(31.0)	48(57.1)	10(11.9)	88.1	8.797	0.003
对照组	85	19(22.4)	40(41)	26(30.6)	63.4	8.797	0.003

?	组别	例数	NT-proBNP(pg/ml)	LVEDD(mm)	LVEF(%)	Tei指数
治疗前	治疗组	84	2 590.58±232.57	57.76±4.99	37.76±5.22	0.59±0.10
	对照组	85	2 579.98±194.06	58.69±5.35	38.16±5.34	0.61±0.13
	t值	?	0.322	－1.170	－0.491	－1.291
	P	?	0.748	0.244	0.624	0.199
治疗后	治疗组	84	1 421.17±125.83^a	54.02±3.81^a	47.71±3.56^a	0.45±0.11^a
	对照组	85	1 774.06±173.31^a	56.90±4.30^a	45.24±3.39^a	0.41±0.11^a
	t值	?	－15.160	－4.616	4.624	2.667
	P	?	<0.001	<0.001	<0.001	0.008

?	组别	例数	NT-proBNP(pg/ml)	LVEDD(mm)	LVEF(%)	Tei指数
治疗前	治疗组	84	2 590.58±232.57	57.76±4.99	37.76±5.22	0.59±0.10
	对照组	85	2 579.98±194.06	58.69±5.35	38.16±5.34	0.61±0.13
	t值	?	0.322	－1.170	－0.491	－1.291
	P	?	0.748	0.244	0.624	0.199
治疗后	治疗组	84	1 421.17±125.83^a	54.02±3.81^a	47.71±3.56^a	0.45±0.11^a
	对照组	85	1 774.06±173.31^a	56.90±4.30^a	45.24±3.39^a	0.41±0.11^a
	t值	?	－15.160	－4.616	4.624	2.667
	P	?	<0.001	<0.001	<0.001	0.008

[1]	Ying Li, Shaoqing Pan, Mingyan Ding, Dandan Sun, Haibo Qu, Peipei Hou, Fang Zhu. Evaluation of left ventricular systolic function and synchrony in advanced atrioventricular block patients with heart failure with preserved ejection fraction after left bundle branch area pacing by real-time three-dimensional echocardiography [J]. Chinese Journal of Medical Ultrasound (Electronic Edition), 2023, 20(04): 430-436.
[2]	Yifan Liu, Di Gao, Jia Dong, Kaiyuan Zhu, Xin Pan, Fenglei Zhang, Dachun Xu, Chunxi Yan. Prognostic value of soluble suppression of tumorigenicity-2 in hospitalized patients with acute heart failure [J]. Chinese Journal of Critical Care Medicine(Electronic Edition), 2023, 16(01): 13-19.
[3]	Hui Pang, Zhenkun Zong, Peng Guo, Peng Wei, Lin Hao. Application of the CHA₂DS₂-VASc score in predicting thromboembolic risk in patients with heart failure [J]. Chinese Journal of Critical Care Medicine(Electronic Edition), 2022, 15(04): 285-290.
[4]	Shanshan Zheng, Zhe Zheng, Jie Huang, Zhongkai Liao, Yunhu Song, Xiaonan Fang, Sheng Liu. Efficacy of intra-aortic balloon pump as bridging therapy for heart transplantation in patients with advanced heart failure and pulmonary hypertension [J]. Chinese Journal of Transplantation(Electronic Edition), 2022, 16(05): 277-284.
[5]	Xuefeng Sun. RAAS inhibitors in the treatment of patients with chronic kidney disease accompanied by heart failure [J]. Chinese Journal of Kidney Disease Investigation(Electronic Edition), 2022, 11(06): 301-306.
[6]	Hongrui Cui, Hongjuan Yang, Baozhen Xu, Jing Wang, Yuwei Gao, Xinghua Wang, Xiuhong Hu. Predictive effect of NT-proBNP combined with BIA on the risk of volume overload and cardiac function damage in maintenance hemodialysis patients [J]. Chinese Journal of Kidney Disease Investigation(Electronic Edition), 2022, 11(03): 132-138.
[7]	Linyang Yu, Meiying Wang, Jianbin Li, Xiaobin Lou, Siyuan Xie, Zhizhong Ma, Haiying Qi, Jia Li. Characteristics of pulmonary arterial pressure and cardiac morphology and function in children with pneumonia and right heart failure in a high altitude area [J]. Chinese Journal of Clinicians(Electronic Edition), 2023, 17(05): 535-544.
[8]	Zhen Wang, Xiaoyue Yang, Kangkang Su, Chaoyang Wang, Shaojie Li, Shuxia Chen, Jian Gu. Progress in understanding of prognostic impact of beta-blockers on patients with heart failure and atrial fibrillation [J]. Chinese Journal of Clinicians(Electronic Edition), 2023, 17(04): 479-482.
[9]	Zhiming Wang, Yueqing Huang, Qinghua Ma, Weihai Chen, Qin Sun, Renlin Yin, Yanming Wu, Fulong Ye, Hua You, Min Huang. Application of "specialty-general practice" integrated management in elderly patients with non-valvular atrial fibrillation and heart failure: a propensity score matching study [J]. Chinese Journal of Clinicians(Electronic Edition), 2022, 16(12): 1188-1193.
[10]	Mingxue Li, Zimo Li, Jianli Tian. Relationship between blood pressure and heart failure: research status and challenges [J]. Chinese Journal of Clinicians(Electronic Edition), 2022, 16(08): 805-809.
[11]	Hongyan Tang, Haijun Dan, Zhihong Gao, Zuoyang Zhang, Shumei Zhai, Shaoyu Wu, Yu Zhang. Specificity and sensitivity of cardiac color Doppler ultrasound in clinical diagnosis of patients with chronic heart failure [J]. Chinese Journal of Clinicians(Electronic Edition), 2022, 16(07): 676-679.
[12]	Weiwei Zong, Dongmei Xu, Xinyue Zhang, Jie Geng. Effect of integrated medical and nursing management mode on medication compliance and complications in elderly patients with heart failure treated with sacubitril/valsartan [J]. Chinese Journal of Clinicians(Electronic Edition), 2022, 16(06): 588-592.
[13]	Yanmei Zhou, Wen Sun, Lin Lin, Juanjuan Chen, Peili Du, Huili Zhang, Jingsi Chen, Lili Du, Dunjin Chen. Diagnosis, treatment and evaluation of preeclampsia complicated with heart failure [J]. Chinese Journal of Obstetric Emergency(Electronic Edition), 2022, 11(04): 228-233.
[14]	Qianwen Kong, Shan Liu, Caihong Zeng, Qingchun Zeng. Observational study of the effects of aerobic and resistance exercise on heart rate variability in patients with heart failure [J]. Chinese Journal of Heart and Heart Rhythm(Electronic Edition), 2023, 11(03): 160-164.
[15]	Chenglin Zhang, Xuemei Li, Huixin Wu, Xiaoyan Li. Construction of nursing quality evaluation index system of volume management in patients with heart failure [J]. Chinese Journal of Heart and Heart Rhythm(Electronic Edition), 2023, 11(03): 173-178.

Please choose a citation manager

Content to export